Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses

被引：5
|
作者：
Janjigian, Yelena Y.
Shitara, Kohei
Ajani, Jaffer
Moehler, Markus
Yao, Jin
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Kowalyszyn, Ruben
Karamouzis, Michalis
Zander, Thomas
Feeney, Kynan
Elimova, Elena
Nathani, Raheel
Novosiadly, Ruslan
Lei, Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT037
引用
收藏
页数：3
相关论文
共 50 条
  • [31] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    Sullivan, Kendall
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
  • [32] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
  • [33] Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
    Qiu, Hai-Bo
    THORACIC CANCER, 2020, 11 (12) : 3419 - 3421
  • [34] First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
    Baas, P.
    Scherpereel, A.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mansfield, A.
    Popat, S.
    Jahan, T.
    Antonia, S.
    Oulkhouir, Y.
    Bautista, Y.
    Cornelissen, R.
    Greillier, L.
    Grossi, F.
    Kowalski, D. M.
    Rodriguez-Cid, J.
    Aanur, P.
    Baudelet, C.
    Zalcman, G.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : E42 - E42
  • [35] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Hu, Nan
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 392 - 392
  • [36] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [37] First-line nivolumab plus ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H
    Daga, H.
    Yu, C-J
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S
    ESMO OPEN, 2022, 7 (01)
  • [38] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) vs (C)
    Moehler, Markus
    Wyrwicz, Lucjan
    Chen, Clara
    Davenport, Eric
    Wang, Jinyi
    Nathani, Raheel
    Kondo, Kaoru
    Elimova, Elena
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 65 - 65
  • [39] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
    Janjigian, Yelena Y.
    Shitara, Kohei
    Moehler, Markus
    Garrido, Marcelo
    Salman, Pamela
    Shen, Lin
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Campos
    Liu, Tianshu
    Schenker, Michael
    Yanez, Patricio
    Tehfe, Mustapha
    Kowalyszyn, Ruben
    Karamouzis, Michalis V.
    Bruges, Ricardo
    Zander, Thomas
    Pazo-Cid, Roberto
    Hitre, Erika
    Feeney, Kynan
    Cleary, James M.
    Poulart, Valerie
    Cullen, Dana
    Lei, Ming
    Xiao, Hong
    Kondo, Kaoru
    Li, Mingshun
    Ajani, Jaffer A.
    LANCET, 2021, 398 (10294): : 27 - 40
  • [40] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Results of nivolumab plus chemotherapy (NIVO plus chemo) versus chemo from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Blum, Steven I.
    Xiao, Hong
    Li, Mingshun
    Kondo, Kaoru
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
12345